A growing number of Byetta lawsuit filings allege use of the drug can increase risks for developing pancreatitis and pancreatic cancer. This is just the latest study to provide evidence that Byetta and similar drugs may pose a risk to the pancreas.
New York, New York (PRWEB) November 25, 2013
As Byetta lawsuit (http://www.byettalawsuit2013.com/ ) claims continue to mount in courts throughout the U.S., Bernstein Liebhard LLP notes the publication of a new study which supports an association between incretin mimetics like Byetta and pancreatic impairment, most notably pancreatitis. The study, which was posted online on November 13th at Informa Healthcare, examined 1,169 adverse reports related to Byetta and other incretin mimetics made to the Italian Spontaneous ADR Reporting Database. Of those, 90 detailed cases of pancreatitis or elevated levels of pancreatic enzyme, leading the authors of the study to conclude that there is an association between the use of drugs like Byetta and pancreatic impairment. They further concluded that patients using this class of Type 2 diabetes should be monitored for these types of side effects.*
“A growing number of Byetta lawsuit filings allege use of the drug can increase risks for developing pancreatitis and pancreatic cancer. This is just the latest study to provide evidence that Byetta and similar drugs may pose a risk to the pancreas.” The Firm is currently offering free case evaluations to patients who took Byetta and were diagnosed with pancreatic cancer, thyroid cancer or pancreatitis.
According to court documents, at least 150 product liability lawsuits involving Byetta and other incretin mimetics are currently pending in a federal multidistrict litigation underway in U.S. District Court, Southern District of California. All of the lawsuits allege that the manufacturers of these medications failed to provide doctors and patients with adequate warnings regarding their potential to cause pancreatic cancer and pancreatitis. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
Brought to market in 2005, Byetta was the first incretin mimetic approved to treat Type 2 diabetes. In recent years, however, a growing body of evidence has found a possible association between the use of Byetta and pancreatic cancers, as well as pancreatitis and thyroid cancer. In 2008, Byetta was the subject of a Drug Safety Communication, after the U.S. Food & Drug Administration (FDA) received a high number of reports involving pancreatitis in patients who took the drug.** In February 2011, research appearing in Gastroenterology, suggested that patients taking Byetta faced a 3-fold increased risk of developing pancreatic cancer, as well as a 6-fold increased risk of pancreatitis. The same study also reported 30 cases of thyroid cancer among Byetta patients.***
This past March, the FDA announced that it was investigating findings from a small study that indicated drugs like Byetta could cause precancerous changes in the cells of the pancreas. However, the FDA has been unable so far to reach a conclusion, though its review is ongoing.
Most recently, a report issued by the Institute for Safe Medicine Practices revealed that the FDA had received 263 reports of pancreatitis, 71 cases of pancreatic cancer, and 14 incidents of thyroid cancer among patients taking Byetta in a single 12-month period.**** In June, the British Medical Journal reported that an analysis of clinical trial data for Byetta and other incretin mimetics indicated that the manufacturers of the medications may have downplayed the potential for pancreatic side effects.*****
Alleged victims of Byetta and pancreatic cancer, pancreatitis, or thyroid cancer may be entitled to financial compensation for their injury-related damages, including medical bills, lost wages, and pain and suffering. Individuals interested in filing a Byetta lawsuit can learn more about their legal options at Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092 today.
*informahealthcare.com/doi/abs/10.1517/14740338.2014.853036, Informa Healthcare, November 13, 2013
**fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm, FDA, August 18, 2008
***gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
****ismp.org/quarterwatch/pdfs/2012Q3.pdf, ISMP, April 2013
*****bmj.com/content/346/bmj.f3680, British Medical Journal, June 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com